These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10613576)

  • 41. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy.
    Johnson LN; Guy ME; Krohel GB; Madsen RW
    Ophthalmology; 2000 Mar; 107(3):521-6. PubMed ID: 10711891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recovery of contour integration in relation to LogMAR visual acuity during treatment of amblyopia in children.
    Chandna A; Gonzalez-Martin JA; Norcia AM
    Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4016-22. PubMed ID: 15505051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amblyopia treatment strategies and new drug therapies.
    Pescosolido N; Stefanucci A; Buomprisco G; Fazio S
    J Pediatr Ophthalmol Strabismus; 2014; 51(2):78-86. PubMed ID: 24410693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of levodopa on visual evoked potential in amblyopia].
    Den D; Long S; Mai G; Wu DZ; Chen G
    Yan Ke Xue Bao; 1997 Dec; 13(4):182-5. PubMed ID: 11326903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levodopa improves procedural motor learning in chronic stroke patients.
    Rösser N; Heuschmann P; Wersching H; Breitenstein C; Knecht S; Flöel A
    Arch Phys Med Rehabil; 2008 Sep; 89(9):1633-41. PubMed ID: 18760148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical profile of moderate amblyopia in children younger than 7 years.
    Pediatric Eye Disease Investigator Group
    Arch Ophthalmol; 2002 Mar; 120(3):281-7. PubMed ID: 11879130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
    Mao ZL; Modi NB
    J Clin Pharmacol; 2016 Aug; 56(8):974-82. PubMed ID: 26632091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic Evaluation of Levodopa Effect on Visual Improvement in Amblyopia: A Meta-analysis.
    Wang SP; Li QX; Li S
    Clin Neuropharmacol; 2020; 43(1):20-25. PubMed ID: 31738189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of drug treatment in children with strabismus and amblyopia.
    Chatzistefanou KI; Mills MD
    Paediatr Drugs; 2000; 2(2):91-100. PubMed ID: 10937461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carbidopa/levodopa for smoking cessation: a pilot study with negative results.
    Hurt RD; Ahlskog JE; Croghan GA; Offord KP; Wolter TD; Croghan IT; Moyer TP
    Nicotine Tob Res; 2000 Feb; 2(1):71-8. PubMed ID: 11072443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship between stereopsis and visual acuity after occlusion therapy for amblyopia.
    Lee SY; Isenberg SJ
    Ophthalmology; 2003 Nov; 110(11):2088-92. PubMed ID: 14597513
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease.
    Tourtellotte WW; Syndulko K; Potvin AR; Hirsch SB; Potvin JH
    Arch Neurol; 1980 Nov; 37(11):723-6. PubMed ID: 7436817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New advances in amblyopia therapy I: binocular therapies and pharmacologic augmentation.
    Kraus CL; Culican SM
    Br J Ophthalmol; 2018 Nov; 102(11):1492-1496. PubMed ID: 29777043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.